Cenegermin receives European Commission marketing authorization

Article

The European Commission has granted marketing authorisation for cenegermin eye drops (Oxervate, Dompé) for the treatment of moderate to severe neurotrophic keratitis.

The European Commission has granted marketing authorisation for cenegermin eye drops (Oxervate, Dompé) for the treatment of moderate to severe neurotrophic keratitis.

It is the first drug authorised by the European Commission for adults in Europe with neurotrophic keratitis, a severely debilitating eye disease which affects fewer than 5 out of 10,000 people.

Related: EMA committee recommends cenegermin for neurotrophic keratitis

Considering the severity of the disease and the lack of viable alternatives, having a therapeutic option that can act on corneal lesions is an important development for the community of ophthalmologists and to the patients themselves,” said Harminder Singh Dua, chair and professor of ophthalmology, University of Nottingham.

Cenegermin received orphan drug designation for neurotrophic keratitis in 2015.

In this condition, damage to the trigeminal nerve or its branches causes loss of sensation in the cornea. In the most severe cases, it can lead to ulcers, aseptic necrosis and corneal perforation, resulting in impaired vision of those affected.

The initial damage can result from herpes simplex and herpes zoster viral infections, trigeminal neuralgia surgery, acoustic neuroma, and toxicity from chronic use of topical ocular medications.

The sensory neurons in the cornea directly influence the integrity of the corneal epithelium; without them epithelial cells swell, lose microvilli, and produce abnormal basal lamina. This can slow mitosis, leading to epithelial breakdown.

This makes the cornea prone to injury that can lead to corneal ulcers, perforation, infection, and scarring.

Discontinuation of medications that caused the syndrome may allow healing, but until now, no medication could restore decreased corneal sensitivity or induce corneal healing.

Cenegermin is the recombinant version of the human nerve growth factor (NGF) discovered by Nobel Laureate Rita Levi Montalcini. This protein is naturally produced by the human body and is involved in the development, maintenance, and survival of nerve cells.

Dompé produces cenegermin through recombinant DNA technology, with the introduction of a gene (DNA) into bacteria, causing them to produce the human nerve growth factor.

Nerve regeneration

 

Administered in the form of eye drops to patients with neurotrophic keratitis, cenegermin could promote nerve regeneration, leading to repair the corneal damage.

Two phase II clinical trials involving 204 patients with moderate and severe neurotrophic keratitis showed that after eight weeks a higher number of patients treated with cenegermin reached a complete corneal healing than patients receiving a placebo.

The most common adverse reactions observed with cenegermin include eye pain, eye inflammation, increased lacrimation, eyelid pain, and foreign body sensation in the eye.

Oxervate will be available as a 20 µg/ml eye drops solution.

Dompé is also exploring the use of cenergermin in other optic neuropathies, such as retinitis pigmentosa, glaucoma, dry eye disease, and retinitis pigmentosa.

Meanwhile, researchers at Yamaguchi University and Hiroshima University are pursuing a similar approach to the treatment of neurotrophic keratitis using a combination of the neurotransmitter substance P and insulin-like growth factor 1 (IGF-1).

Researchers elsewhere are investigating extracellular matrix regenerators, sulfate analogs that protect and stabilize the action of such growth factors as FGF-1, FGF-2, TGFbeta-1, and VEGF.

These compounds stimulate the synthesis of collagen and glycosamineglycanes and inhibit the action of enzymes such as elastase, haparanase, or plasmin, all of which enhances the process of extracellular matrix remodeling and regeneration. A phase III multicenter trial of one formulation, Cacicol (Thea) is also underway.

Autologous serum and platelet-rich plasma are also being researched.

Oxervate is Dompé’s first biotechnical drug. “Neurotrophic keratitis is a rare disease that is particularly debilitating, and until now, patients have had no treatment options,” said Eugenio Aringhieri, the company’s chief executive officer. “The European Commission adopted decision is a milestone for patients affected by this disease, for the research in this sector, and for our Company.”

The company will now seek approval for the drug in markets outside Europe, he said.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.